Search

Your search keyword '"Morisco F"' showing total 98 results

Search Constraints

Start Over You searched for: Author "Morisco F" Remove constraint Author: "Morisco F" Topic business Remove constraint Topic: business
98 results on '"Morisco F"'

Search Results

1. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2. Pattern of macrovascular invasion in hepatocellular carcinoma

3. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

4. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

5. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019

6. Platelets and hepatocellular cancer: Bridging the bench to the clinics

7. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

8. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

9. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

10. Metabolic disorders across hepatocellular carcinoma in Italy

11. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres

12. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

13. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

14. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

15. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

16. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study

17. HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey

18. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma

19. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study

20. HUMAN LEUKOCYTE ANTIGEN POLYMORPHISMS IN ITALIAN PRIMARY BILIARY CIRRHOSIS: A MULTICENTER STUDY OF 664 PATIENTS AND 1992 HEALTHY CONTROLS

21. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

22. Chronic hepatitis B in Italy: New features of an old disease - Approaching the universal prevalence of hepatitis B e antigen-negative cases and the eradication of hepatitis D infection

23. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

24. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

25. The aetiology of chronic hepatitis in Italy: results from a multicentre national study

26. The association between education level and chronic liver disease of any etiology

27. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

28. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter

29. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

30. An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

31. Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey

32. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

33. HepaDisk – A new quality of life questionnaire for HCV patients

34. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection

35. Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy

36. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

37. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

38. A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study

39. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

40. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

41. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

42. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

43. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

44. Years of life that could be saved from prevention of hepatocellular carcinoma

45. HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome

46. Hepatitis B vaccine coverage and risk factors for lack of vaccination in subjects with HBsAg negative liver cirrhosis in Italy: still, much work should be done

47. Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium

48. Surveillance for hepatocellular carcinoma with a 3-months interval in 'extremely high-risk' patients does not further improve survival

49. Anti-hepatitis A virus seroprevalence and seroconversion in a cohort of patients with chronic viral hepatitis

50. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients

Catalog

Books, media, physical & digital resources